IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D.
Read moreGeneva, 3 September 2020 – Seven months into the pandemic, the innovative biopharmaceutical industry continues to step up work on researching and testing therapeutics that could lower mortality rates or lessen the severity of COVID-19. Over recent months, the results of rigorous clinical trials of repurposed medicines to achieve quick wins have been mixed, while...
Read moreGeneva, 28 August 2020 – In the face of an unprecedented public health and economic crisis, the world’s leading innovative vaccine companies are working in partnership with international organizations, governments, academia and many others across the world in answering the call to develop novel vaccines against SARS-CoV-2. Our goal is to provide vaccines to people once...
Read moreGeneva, August 25, 2020 IFPMA thanks the WHO AFRO for this opportunity to share a statement at this 70th session of the WHO Regional meeting. IFPMA represents leading research-based biopharmaceutical companies and national and regional industry associations across the world, including Africa. IFPMA believes that a well-coordinated, inclusive, multi-stakeholder approach and solidarity are the only...
Read moreOn 24 July, Thomas Cueni, IFPMA Director General, joined Imogen Foulkes for the Inside Geneva podcast on Swiss Info, to talk about the development, production and eventual distribution of COVID-19 vaccines. Their discussion highlighted the importance of broad-based collaborative efforts among all stakeholders as well as the vital necessity of leaving no one behind and...
Read morePublished on Thomas Cueni’s LinkedIn profile. Last Wednesday, I sat down with @Chatham House’s @Emma Ross (moderator) and epidemiologist Professor @David L. Heymann to discuss the latest science and developments in the #COVID19 pandemic. During the interview, we discussed how the pharmaceutical industry is collaborating on an unprecedented scale to develop COVID-19 technologies and tools, the...
Read moreThis paper is based on the biopharmaceutical research-based industry’s experience to date with inspections conducted since the pandemic. It consolidates industry lessons learned from working with these inspection tools. It is meant to complement efforts ongoing in other industry organizations such as EFPIA and PhRMA.
Read moreDoping in sport primarily involves the misuse and abuse of new chemical entities in development and of commercially available medicines. Doping affects the fairness of sport competitions by illegally enhancing athletic performance, causes potentially harmful health effects and violates the spirit of sport. Not only the elite athlete population is affected, but also larger groups...
Read moreGeneva / Montreal, 28 July 2020: The World Anti-Doping Agency (WADA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have signed a memorandum of understanding (MOU) that broadens the scope of information shared about marketed products as well as biomedical products that are still in the early stages of research and development, with...
Read moreThe purpose of the various IFPMA “Notes for Guidance” is to provide additional interpretation and further guidance in relation to the relevant provisions of the Code of Practice. Notes for Guidance are non-binding and must be read with the spirit of the Code in mind and always in accordance with applicable laws and regulations and other applicable industry codes.
Read more